• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.

作者信息

Matesanz M, Poza A, Iñurrieta A, Fernández-Diaz E, Arroyo M, Domínguez I, Candel F J

机构信息

Francisco Javier Candel, Clinical Microbiology and Infectious Diseases IdISSC and IML Health institutes Hospital Clínico San Carlos. Madrid. Spain.

出版信息

Rev Esp Quimioter. 2021 Aug;34(4):396-399. doi: 10.37201/req/026.2021. Epub 2021 May 6.

DOI:10.37201/req/026.2021
PMID:33956412
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8329578/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6271/8329578/f58967f51d1f/revespquimioter-34-396-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6271/8329578/6ef9d615c92e/revespquimioter-34-396-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6271/8329578/f58967f51d1f/revespquimioter-34-396-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6271/8329578/6ef9d615c92e/revespquimioter-34-396-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6271/8329578/f58967f51d1f/revespquimioter-34-396-g002.jpg

相似文献

1
Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.达巴万星对耐甲氧西林金黄色葡萄球菌引起的复杂性骨关节炎感染进行一年治疗后，疗效显著且安全性良好。
Rev Esp Quimioter. 2021 Aug;34(4):396-399. doi: 10.37201/req/026.2021. Epub 2021 May 6.
2
Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.达巴万星治疗耐甲氧西林金黄色葡萄球菌心内膜炎失败
J Clin Pharm Ther. 2018 Feb;43(1):101-103. doi: 10.1111/jcpt.12580. Epub 2017 Jun 19.
3
Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.多次每周使用达巴万星治疗耐甲氧西林金黄色葡萄球菌引起的原发性椎体骨髓炎：一例报告
Am J Case Rep. 2017 Dec 9;18:1315-1319. doi: 10.12659/ajcr.905930.
4
Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.达巴万星治疗耐甲氧西林金黄色葡萄球菌（MRSA）所致骨髓炎的大鼠模型中的治疗潜力。
Int J Antimicrob Agents. 2020 Jul;56(1):106021. doi: 10.1016/j.ijantimicag.2020.106021. Epub 2020 May 18.
5
[Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon].达巴万星及其在治疗耐甲氧西林金黄色葡萄球菌引起的上肢蜂窝织炎中的应用
Klin Mikrobiol Infekc Lek. 2020 Jun;26(2):51-53.
6
French national cohort of first use of dalbavancin: A high proportion of off-label use.法国首用达巴万星的全国队列研究：高比例的超适应证用药。
Int J Antimicrob Agents. 2019 Nov;54(5):668-672. doi: 10.1016/j.ijantimicag.2019.08.006. Epub 2019 Aug 7.
7
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌的新型抗菌药物。
Crit Care Resusc. 2009 Dec;11(4):282-6.
8
Dalbavancin for the treatment of acute bacterial skin and skin structure infections.达巴万星用于治疗急性细菌性皮肤和皮肤结构感染。
Infez Med. 2015 Dec;23(4):313-7.
9
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.治疗药物监测在评估达巴万星治疗葡萄球菌骨关节感染的最佳目标达成时间中的作用：概念验证。
Int J Antimicrob Agents. 2021 Nov;58(5):106445. doi: 10.1016/j.ijantimicag.2021.106445. Epub 2021 Oct 3.
10
Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.达巴万星治疗耐甲氧西林金黄色葡萄球菌所致大鼠胸骨骨髓炎合并纵隔炎的疗效
J Antimicrob Chemother. 2016 Feb;71(2):460-3. doi: 10.1093/jac/dkv357. Epub 2015 Oct 30.

引用本文的文献

1
Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.达巴万星作为人工假体感染患者的抑制性抗生素治疗：疗效与安全性。
Front Pharmacol. 2023 Jun 28;14:1185602. doi: 10.3389/fphar.2023.1185602. eCollection 2023.

本文引用的文献

1
Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.达巴万星治疗革兰氏阳性菌引起的人工关节感染：低剂量策略的建议。一项回顾性队列研究。
Rev Esp Quimioter. 2019 Dec;32(6):532-538. Epub 2019 Oct 22.
2
Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.达巴万星治疗骨髓炎和关节炎感染的安全性和疗效。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02280-18. Print 2019 May.
3
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).
达巴万星可减少耐甲氧西林金黄色葡萄球菌（MRSA）和耐甲氧西林表皮葡萄球菌（MRSE）的生物被膜。
Eur J Clin Microbiol Infect Dis. 2017 Apr;36(4):677-680. doi: 10.1007/s10096-016-2845-z. Epub 2016 Nov 28.
4
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.单剂量与每周一次达巴万星治疗急性细菌性皮肤和皮肤结构感染的随机临床试验
Clin Infect Dis. 2016 Mar 1;62(5):545-51. doi: 10.1093/cid/civ982. Epub 2015 Nov 26.
5
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.达巴万星的延长给药及在骨骼和关节组织中的分布。
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.
6
Once-weekly dalbavancin versus daily conventional therapy for skin infection.每周一次的达巴万星与每日常规疗法治疗皮肤感染。
N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480.
7
Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).美国达巴万星的药物光谱和效力更新：来自 SENTRY 抗菌监测计划（2011 年）的报告。
Diagn Microbiol Infect Dis. 2013 Mar;75(3):304-7. doi: 10.1016/j.diagmicrobio.2012.11.024. Epub 2013 Jan 26.
8
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.达巴万星对全球81673株革兰氏阳性细菌分离株的活性。
Antimicrob Agents Chemother. 2009 Mar;53(3):1260-3. doi: 10.1128/AAC.01453-08. Epub 2009 Jan 5.
9
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.人用达巴万星（一种半合成糖肽类抗生素）的药代动力学及每周一次给药的理论依据。
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii25-30. doi: 10.1093/jac/dki008.